Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs

Breast cancer is the most common malignant tumors in females. Although the conventional treatment has demonstrated a certain effect, some limitations still exist. The Rho guanosine triphosphatase (GTPase) Cdc42 (Cell division control protein 42 homolog) is often upregulated by some cell surface rece...

Full description

Bibliographic Details
Main Authors: Yu Zhang, Jun Li, Xing-Ning Lai, Xue-Qiao Jiao, Jun-Ping Xiong, Li-Xia Xiong
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/8/2/146
id doaj-8e3f7af0cb9447bb903b4ff22541f2dc
record_format Article
spelling doaj-8e3f7af0cb9447bb903b4ff22541f2dc2020-11-24T22:09:56ZengMDPI AGCells2073-44092019-02-018214610.3390/cells8020146cells8020146Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAsYu Zhang0Jun Li1Xing-Ning Lai2Xue-Qiao Jiao3Jun-Ping Xiong4Li-Xia Xiong5Department of Pathophysiology, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, ChinaDepartment of Pathophysiology, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, ChinaDepartment of Pathophysiology, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, ChinaDepartment of Pathophysiology, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, ChinaDepartment of Pathophysiology, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, ChinaDepartment of Pathophysiology, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, ChinaBreast cancer is the most common malignant tumors in females. Although the conventional treatment has demonstrated a certain effect, some limitations still exist. The Rho guanosine triphosphatase (GTPase) Cdc42 (Cell division control protein 42 homolog) is often upregulated by some cell surface receptors and oncogenes in breast cancer. Cdc42 switches from inactive guanosine diphosphate (GDP)-bound to active GTP-bound though guanine-nucleotide-exchange factors (GEFs), results in activation of signaling cascades that regulate various cellular processes such as cytoskeletal changes, proliferation and polarity establishment. Targeting Cdc42 also provides a strategy for precise breast cancer therapy. In addition, Cdc42 is a potential target for several types of non-coding RNAs including microRNAs and lncRNAs. These non-coding RNAs is extensively involved in Cdc42-induced tumor processes, while many of them are aberrantly expressed. Here, we focus on the role of Cdc42 in cell morphogenesis, proliferation, motility, angiogenesis and survival, introduce the Cdc42-targeted non-coding RNAs, as well as present current development of effective Cdc42-targeted inhibitors in breast cancer.https://www.mdpi.com/2073-4409/8/2/146breast cancerCdc42cytoskeleton remodelingtumor progressiontargeted therapynon-coding RNAs
collection DOAJ
language English
format Article
sources DOAJ
author Yu Zhang
Jun Li
Xing-Ning Lai
Xue-Qiao Jiao
Jun-Ping Xiong
Li-Xia Xiong
spellingShingle Yu Zhang
Jun Li
Xing-Ning Lai
Xue-Qiao Jiao
Jun-Ping Xiong
Li-Xia Xiong
Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs
Cells
breast cancer
Cdc42
cytoskeleton remodeling
tumor progression
targeted therapy
non-coding RNAs
author_facet Yu Zhang
Jun Li
Xing-Ning Lai
Xue-Qiao Jiao
Jun-Ping Xiong
Li-Xia Xiong
author_sort Yu Zhang
title Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs
title_short Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs
title_full Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs
title_fullStr Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs
title_full_unstemmed Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs
title_sort focus on cdc42 in breast cancer: new insights, target therapy development and non-coding rnas
publisher MDPI AG
series Cells
issn 2073-4409
publishDate 2019-02-01
description Breast cancer is the most common malignant tumors in females. Although the conventional treatment has demonstrated a certain effect, some limitations still exist. The Rho guanosine triphosphatase (GTPase) Cdc42 (Cell division control protein 42 homolog) is often upregulated by some cell surface receptors and oncogenes in breast cancer. Cdc42 switches from inactive guanosine diphosphate (GDP)-bound to active GTP-bound though guanine-nucleotide-exchange factors (GEFs), results in activation of signaling cascades that regulate various cellular processes such as cytoskeletal changes, proliferation and polarity establishment. Targeting Cdc42 also provides a strategy for precise breast cancer therapy. In addition, Cdc42 is a potential target for several types of non-coding RNAs including microRNAs and lncRNAs. These non-coding RNAs is extensively involved in Cdc42-induced tumor processes, while many of them are aberrantly expressed. Here, we focus on the role of Cdc42 in cell morphogenesis, proliferation, motility, angiogenesis and survival, introduce the Cdc42-targeted non-coding RNAs, as well as present current development of effective Cdc42-targeted inhibitors in breast cancer.
topic breast cancer
Cdc42
cytoskeleton remodeling
tumor progression
targeted therapy
non-coding RNAs
url https://www.mdpi.com/2073-4409/8/2/146
work_keys_str_mv AT yuzhang focusoncdc42inbreastcancernewinsightstargettherapydevelopmentandnoncodingrnas
AT junli focusoncdc42inbreastcancernewinsightstargettherapydevelopmentandnoncodingrnas
AT xingninglai focusoncdc42inbreastcancernewinsightstargettherapydevelopmentandnoncodingrnas
AT xueqiaojiao focusoncdc42inbreastcancernewinsightstargettherapydevelopmentandnoncodingrnas
AT junpingxiong focusoncdc42inbreastcancernewinsightstargettherapydevelopmentandnoncodingrnas
AT lixiaxiong focusoncdc42inbreastcancernewinsightstargettherapydevelopmentandnoncodingrnas
_version_ 1725809972888993792